Unlike TAAs, which may also be expressed in normal tissues, KRAS-derived neoantigens are tumor-specific, reducing the risk of off-target effects and making them highly attractive candidates for cancer immunotherapy [52]. This evidence concerns the gene KRAS and neoplasm.